Welspun Enterprises Grants 6,00,000 Stock Options Under ESOP Scheme 2022

1 min read     Updated on 24 Mar 2026, 01:29 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Welspun Enterprises Limited has granted 6,00,000 stock options under its ESOP Scheme 2022 to eligible employees, with Board approval received on March 23, 2026. The options carry an exercise price of Rs. 462 per option and will vest 25% annually over four years, starting from the first anniversary of grant date. Each option represents one equity share of Rs. 10 face value, with employees having one year from the last vesting date to exercise their options.

powered bylight_fuzz_icon
35841567

*this image is generated using AI for illustrative purposes only.

Welspun enterprises has granted 6,00,000 stock options to eligible employees under its Employee Benefit Scheme 2022, following Board approval on March 23, 2026. The decision was made based on recommendations from the company's Nomination & Remuneration Committee, which met on March 21, 2026.

Stock Option Grant Details

The comprehensive details of the ESOP grant reveal structured employee benefits designed to align workforce interests with company performance:

Parameter Details
Total Options Granted 6,00,000 (Six Lakh) Options
Exercise Price Rs. 462 per Option
Shares Covered 6,00,000 equity shares of Rs. 10 each
Vesting Schedule 25% annually over 4 years
Exercise Period 1 year from last vesting date

Vesting and Exercise Framework

The stock options follow a systematic vesting approach designed to encourage long-term employee retention. Under the approved structure, 25% of the granted options will vest each year over a four-year period, beginning from the first anniversary of the grant date. This graduated vesting ensures employees remain committed to the organization's long-term objectives.

The exercise period provides flexibility to option holders, allowing them one full year from the date of last vesting to exercise their vested options. This timeframe gives employees adequate opportunity to make informed decisions about exercising their stock options based on market conditions and personal financial planning.

Regulatory Compliance

The ESOP grant complies with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, ensuring adherence to regulatory frameworks governing employee stock option schemes. The company has made the requisite disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The intimation follows SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, demonstrating the company's commitment to transparent corporate governance practices. Complete details of the grant have been made available on the company's website at www.welspunenterprises.com for stakeholder reference.

Historical Stock Returns for Welspun Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
+0.52%-3.99%-10.81%-16.76%-13.99%+277.31%

How might this significant ESOP grant impact Welspun Enterprises' earnings per share dilution over the next four years?

What does the Rs. 462 exercise price suggest about management's confidence in the company's future stock performance?

Could this employee retention strategy signal upcoming major projects or expansion plans that require stable workforce commitment?

Welspun Enterprises Files Q3 FY26 Deviation Statement for Convertible Warrants

2 min read     Updated on 05 Feb 2026, 12:17 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Welspun Enterprises submitted its quarterly deviation statement for Q3 FY26, confirming no deviation in the utilization of Rs 1,000.00 crore raised through convertible warrants. The company received Rs 250.00 crore during the quarter, with remaining funds to be received upon warrant conversion within 18 months, while maintaining full regulatory compliance under SEBI guidelines.

powered bylight_fuzz_icon
31756686

*this image is generated using AI for illustrative purposes only.

Welspun Enterprises Limited has submitted its statement of deviation or variation for the quarter ended December 31, 2025, confirming no deviation in the utilization of proceeds from its convertible warrants issued through preferential allotment. The statement, filed under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was reviewed by the Audit Committee and Board of Directors at their respective meetings held on February 04, 2026.

Issue Details and Fund Raising

The company raised funds through convertible warrants with a total issue size of Rs 1,000.00 crore via preferential issue on October 15, 2025. During the quarter ended December 31, 2025, the company received Rs 250.00 crore, representing 25% of the issue size as subscription amount. The remaining 75% amounting to Rs 750.00 crore will be received upon exercise of conversion option by warrant holders within 18 months from the allotment date of December 01, 2025.

Parameter: Details
Total Issue Size: Rs 1,000.00 crore
Date of Fund Raising: October 15, 2025
Amount Received: Rs 250.00 crore
Amount Pending: Rs 750.00 crore
Conversion Window: 18 months from December 01, 2025

Fund Utilization and Allocation

The deviation statement confirms no utilization of issue proceeds during the quarter ended December 31, 2025. The funds are allocated for two primary objectives: Rs 750.00 crore for infusion into construction of a 6-lane partially elevated highway corridor from Pune to Shirur (NH-753F) in Maharashtra under DFBOT (Toll) mode with a 29-year concession period, and Rs 250.00 crore for general corporate purposes.

Object: Original Allocation (Rs crore) Modified Allocation (Rs crore) Funds Utilized (Rs crore) Deviation Amount (Rs crore)
Highway Construction Project: 750.00 N.A. N.A. Nil
General Corporate Purpose: 250.00 N.A. N.A. Nil
Total: 1,000.00 N.A. N.A. Nil

Regulatory Compliance and Monitoring

CRISIL Ratings Limited serves as the monitoring agency for the convertible warrants issue. The deviation statement indicates no deviation or variation in the use of funds raised, with no changes in terms of contract or objects requiring shareholder approval. Both the Audit Committee and auditors provided no adverse comments on the fund utilization during the quarter.

Compliance Parameter: Status/Details
Monitoring Agency: CRISIL Ratings Limited
Deviation in Fund Use: No
Shareholder Approval Required: Not applicable
Audit Committee Comments: None
Auditor Comments: None

Corporate Governance and Disclosure

The statement was signed by Nidhi Tanna, Company Secretary (ACS-30465), and submitted to BSE Limited and National Stock Exchange of India Limited on February 04, 2026. The company maintains transparency by hosting all relevant information on its website at www.welspunenterprises.com . The filing ensures compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding quarterly reporting requirements for fund utilization.

Historical Stock Returns for Welspun Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
+0.52%-3.99%-10.81%-16.76%-13.99%+277.31%

More News on Welspun Enterprises

1 Year Returns:-13.99%